A Randomized, Multicenter, Phase III Open-Label Study of the Efficacy and Safety of Trastuzumab Emtansine Versus Lapatinib Plus Capecitabine in Chinese Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy
Phase of Trial: Phase III
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Trastuzumab emtansine (Primary) ; Capecitabine; Lapatinib
- Indications Breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Roche
- 14 Sep 2017 Planned End Date changed from 29 Oct 2020 to 27 May 2020.
- 13 Jun 2017 Status changed from not yet recruiting to recruiting.
- 23 Mar 2017 New trial record